Novavax Inc said on Monday its combined flu and Covid-19 vaccine produced functional antibodies against influenza and the coronavirus in a preclinical study.
The company said the NanoFlu/NVX-CoV2373 vaccine elicited robust responses to both influenza A and B and protected against the SARS-CoV-2 virus.
“Seasonal influenza and Covid-19 combination vaccines will likely be critical to combating emerging Covid-19 variants,” said Russell Wilson, the executive vice president and NanoFlu general manager of Novavax.
Hamsters that received the combined vaccine had heightened levels of Covid-19 antibodies two weeks after the first immunization, which increased significantly after a second dose, compared to animals that received the Covid-19 vaccine, NVX-CoV2373, alone, the company said.
Novavax said it expects to start clinical studies of the combined vaccine by the end of 2021.
Explore the profound effects of excessive screen time on your child’s behavior and development. Discover…
Discover how simple daily changes in your diet and lifestyle can significantly improve your heart…
This article explores the common misconception that brain tumours primarily affect older adults, revealing the…
The first-ever ovarian cancer vaccine is poised to change the landscape of women's health by…
As dengue and chikungunya cases rise in Delhi during the monsoon season, understanding prevention strategies…
Skincare is a significant concern for women (and increasingly, men), with the quest for perfect,…